Systemic treatment-free period following dupilumab discontinuation for atopic dermatitis: A nationwide cohort study.

There is limited data regarding discontinuation of dupilumab in atopic dermatitis (AD). This study aimed to determine the proportion of patients with a systemic treatment-free period of ≥12 months following dupilumab discontinuation, and to describe patient characteristics and care trajectories. We conducted a cohort study including 7,214 patients with severe AD treated with dupilumab for ≥6 months. Overall, 900 patients (12%) discontinued dupilumab for ≥12 months, without switching to another systemic treatment. Within this group, 72% remained off-systemic treatment throughout the follow-up, 22% restarted treatment with dupilumab and 6% switched to another systemic treatment. Patients who did not receive further systemic treatment tended to be older and, in the year following discontinuation, required fewer topical corticosteroids and fewer dermatologist consultations compared to patients who restarted systemic treatment. In conclusion, among patients who discontinued dupilumab for ≥12 months, most did not receive further systemic treatment throughout follow-up, suggesting that a systemic treatment-free period may be achievable in AD.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-13
DOI
https://doi.org/10.1093/ced/llag467
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Systemic treatment-free period following dupilumab discontinuation for atopic dermatitis: A nationwide cohort study.

Lucie‐Marie Scailteux, Sandrine Kerbrat, C. Droitcourt, Delphine Staumont-Sallé et al.
4 links
PubMed
Dermatology and Skin Diseases
article

Systemic treatment-free period following dupilumab discontinuation for atopic dermatitis: A nationwide cohort study.

Lucie‐Marie Scailteux, Sandrine Kerbrat, C. Droitcourt, Delphine Staumont-Sallé, Marion Gundelwein
article en

Abstract

There is limited data regarding discontinuation of dupilumab in atopic dermatitis (AD). This study aimed to determine the proportion of patients with a systemic treatment-free period of ≥12 months following dupilumab discontinuation, and to describe patient characteristics and care trajectories. We conducted a cohort study including 7,214 patients with severe AD treated with dupilumab for ≥6 months. Overall, 900 patients (12%) discontinued dupilumab for ≥12 months, without switching to another systemic treatment. Within this group, 72% remained off-systemic treatment throughout the follow-up, 22% restarted treatment with dupilumab and 6% switched to another systemic treatment. Patients who did not receive further systemic treatment tended to be older and, in the year following discontinuation, required fewer topical corticosteroids and fewer dermatologist consultations compared to patients who restarted systemic treatment. In conclusion, among patients who discontinued dupilumab for ≥12 months, most did not receive further systemic treatment throughout follow-up, suggesting that a systemic treatment-free period may be achievable in AD.

PubMed
Inserm (FR), École des Hautes Études en Santé Publique (FR), Université de Lille (FR), Institut de Recherche en Santé, Environnement et Travail (FR), Centre Hospitalier Universitaire de Rennes (FR), Institute for Translational Research in Inflammation (FR), Université de Rennes (FR)
Good health and well-being
Dermatology and Skin Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon